The DFVision^® 3D Fluorescence Endoscope, a core imaging component of the Toumai^® Multi-Port Laparoscopic Surgical Robot (Toumai^® Robot), has recently received EU CE certification. This marks another significant recognition of the Toumai^® surgical robot by international regulatory authorities and underscores its readiness for adoption in European and other high-end global markets.

Leveraging multimodal fluorescence capabilities, the system allows surgeons to switch seamlessly among eight fluorescence display modes. In complex, multi-specialty procedures, it enhances tumor detection precision and provides a clearer operative field, enabling surgeons to accurately identify lesions, vascular structures, and tissue perfusion. These features improve surgical safety, operational efficiency, and patient outcomes, and are expected to accelerate the commercialization of Toumai^® Robot in Europe and globally, further strengthening the presence of “Made in China” in the international surgical robotics market.

The Toumai^® fluorescence imaging system uses indocyanine green (ICG) as a contrast agent. By independently capturing visible and near-infrared spectra and combining multispectral fusion technology with an innovative dynamic fluorescence gain algorithm, it achieves seamless integration of visible-light and fluorescence images. This enables real-time visualization of tissue function, blood perfusion, and tumor margins during surgery, helping surgeons differentiate tumors from surrounding healthy tissue with greater precision, detect microscopic residual lesions, and monitor critical vessels and functional structures. These capabilities significantly enhance surgical safety and radicality, providing strong support for complex or minimally invasive procedures.

The system maintains synchronized focal planes across all eight fluorescence modes, allowing surgeons to view both fluorescent signals and non-fluorescent tissue details in a single image. This overcomes the limitations of traditional black-and-white fluorescence imaging and enables surgeons to identify tissue, locate lesions, perform resections, and verify completeness without frequent mode switching, greatly improving efficiency, convenience, safety, and precision.

After years of foundational R&D, the MedBot team has achieved 10^⁻⁶-level optical filtering performance for DFVision^®, delivering high fluorescence sensitivity and signal stability across the full depth of field. This allows the clear detection of low-dose micro-metastases with sharp margins, further enhancing surgical precision.

To date, the Toumai^® Robot has obtained market access in over 60 countries and regions, achieved commercial deployment in more than 40 countries, and completed over 15,000 multi-specialty surgical procedures, including more than 700 remote surgeries across 20+ countries and regions. It has set over 60 world-first surgical milestones and is currently the only surgical robotic system globally compatible with 5G, GEO/LEO satellites, and broadband networks, with approvals in multiple countries.